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 Abstract 
 Objective. To determine the infl uence of ischaemic cardiovascular (CV) risk on prescription of non-steroidal anti-infl am-
matory drugs (NSAIDs) by general practitioners (GPs) in patients with musculoskeletal complaints.  Design. Cohort study. 
 Setting. A healthcare database containing the electronic GP medical records of over one million patients throughout the 
Netherlands.  Patients. A total of 474 201 adults consulting their GP with a new musculoskeletal complaint between 2000 
and 2010. Patients were considered at high CV risk if they had a history of myocardial infarction, angina pectoris, stroke, 
transient ischaemic attack, or peripheral arterial disease, and at low CV risk if they had no CV risk factors.  Main outcome 
measures. Frequency of prescription of non-selective (ns)NSAIDs and selective cyclooxygenase-2 inhibitors (coxibs).  Results. 
Overall, 24.4% of patients were prescribed an nsNSAID and 1.4% a coxib. Of the 41,483 patients with a high CV risk, 
19.9% received an nsNSAID and 2.2% a coxib. These patients were more likely to be prescribed a coxib than patients with 
a low CV risk (OR 1.9, 95% CI 1.8 – 2.0). Prescription of nsNSAIDs decreased over time in all risk groups and was lower 
in patients with a high CV risk than in patients with a low CV risk (OR 0.8, 95% CI 0.7 – 0.8).  Conclusion. Overall, patients 
with a high CV risk were less likely to be prescribed an NSAID for musculoskeletal complaints than patients with a low 
CV risk. Nevertheless, one in fi ve high CV risk patients received an NSAID, indicating that there is still room for improve-
ment. 
 Key Words:  Cardiovascular diseases ,  general practice ,  musculoskeletal diseases ,  non-steroidal anti-infl ammatory agents , 
 pharmacoepidemiology ,  The Netherlands 
or as a second choice if paracetamol fails to provide 
suffi cient pain relief [1 – 6]. The use of NSAIDs is 
known to be associated with peptic ulcer disease and 
its complications, most notably upper gastrointesti-
nal (UGI) bleeding, obstruction, and perforation 
[7,8]. The need to limit these UGI complications led 
to the development of selective cyclooxygenase-2 
inhibitors (coxibs), which are associated with a sig-
nifi cantly lower incidence of UGI complications 
 Introduction 
 Non-steroidal anti-infl ammatory drugs (NSAIDs) 
are widely used in the treatment of musculoskeletal 
(MSK) complaints because of their analgesic and anti-
infl ammatory properties. International and national 
guidelines on various MSK complaints, such as back 
pain, shoulder pain, and osteoarthritis, recommend 
prescribing NSAIDs, either as a fi rst-choice analgesic 
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when compared with traditional, non-selective 
NSAIDs (nsNSAIDs) [9 – 12]. 
 However, shortly after the introduction of coxibs, 
concerns were raised regarding their cardiovascular 
(CV) safety profi le. In September 2004, rofecoxib was 
withdrawn from world markets after a randomized 
controlled trial showed the incidence of stroke, myo-
cardial infarction, or sudden cardiac death in patients 
taking rofecoxib was twice that of patients taking a 
placebo [13]. An increased risk of ischaemic CV events 
was also observed in studies of other coxibs, leading 
the European Medicines Agency to contraindicate the 
use of any coxib in patients with established ischaemic 
heart disease, stroke or peripheral arterial disease in 
2005 [14]. Since then, there is increasing evidence 
that the risk of ischaemic CV events is increased not 
only by the use of coxibs but also by the use of 
nsNSAIDs, with the possible exception of naproxen 
[15 – 18]. Recent guidelines and consensus therefore 
recommend avoiding the prescription of NSAIDs in 
general in patients at high CV risk [19 – 21]. 
 In this population-based cohort study, we aimed 
to examine the association between ischaemic CV 
risk and the prescription of NSAIDs in patients with 
MSK complaints. In addition, we aimed to deter-
mine the infl uence of demographic factors, prior 
NSAID prescription, the type of MSK complaint 
presented and the presence of UGI risk factors and 
renal insuffi ciency on NSAID prescription in this 
group of patients. 
 Material and methods 
 Setting 
 A cohort study was conducted in the Integrated 
Primary Care Information (IPCI) database. This 
primary health care database contains the electronic 
patient records of over one million patients registered 
with GPs throughout the Netherlands. In the 
Netherlands, all 16.8 million citizens are registered 
with a GP, who forms the fi rst point of care and acts 
as a gatekeeper in a two-way exchange of information 
with secondary care. The electronic medical record 
of each patient can therefore be assumed to contain 
all relevant medical information, including medical 
fi ndings and diagnoses from secondary care. Further 
details of the database have been described elsewhere 
[22,23]. 
 Study cohort 
 The study population comprised all patients    18 
years of age newly diagnosed with a MSK complaint 
between 1 January 2000 and 31 December 2010. 
Diagnoses were considered new if the patient had not 
been diagnosed with the same MSK complaint in the 
six months prior to consultation. Only patients with 
at least 12 months of valid database history prior to 
study entry were included. Diagnoses of MSK 
complaints were identifi ed based on International 
Classifi cation for Primary Care (ICPC) coding [24]. 
If the patient consulted his/her GP again with the 
same complaint within six months of initial diagno-
sis, this consultation was considered part of the same 
MSK complaint episode. For each patient, only the 
fi rst newly diagnosed complaint episode was included. 
The date of fi rst consultation was considered the 
index date. 
 Cardiovascular risk, upper gastrointestinal risk, 
and renal insuffi ciency 
 In defi ning CV risk, UGI risk, and renal insuffi ciency 
we aimed to conform to Dutch prescription guide-
lines as much as possible. For cardiovascular risk, no 
Dutch guideline is currently available, but a national 
consensus report was published in 2009 containing 
prescription recommendations [21]. In line with this 
report, patients were considered at high CV risk if 
they had a history of myocardial infarction, angina 
pectoris, stroke, transient ischaemic attack, or periph-
eral arterial disease prior to the index date. They were 
considered at moderate CV risk if they did not have 
one of the risk factors described above but did have 
a history of diabetes, hypertension, or hyperlipidae-
mia. Patients without any of these CV risk factors 
were considered at low CV risk. In addition, risk fac-
tors for the occurrence of UGI complications were 
identifi ed. Based on the most recent Dutch guideline 
on the prescription of NSAIDs [25], patients were 
considered at high UGI risk if they had a history of 
upper gastrointestinal bleeding or ulceration, were 
 International guidelines recommend avoiding the 
prescription of NSAIDs in patients at high ischae-
mic cardiovascular risk. In this study, we found 
that: 
 NSAIDs are prescribed in one in fi ve patients  •
with a high cardiovascular risk. 
 Prescription of coxibs is higher in patients  •
with a high cardiovascular risk than in those 
with a low cardiovascular risk. 
 NSAID prescription decreased over time in  •
all risk groups, but it appears that general 
practitioners do not fully consider the car-
diovascular risks associated with NSAID 
use, indicating that there is room for 
improvement. 
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aged over 70 years or had two or more of the follow-
ing risk factors: age 60 – 70 years, history of heart 
failure, diabetes, or severe rheumatoid arthritis, 
use of antithrombotics, corticosteroids, or selective 
serotonin reuptake inhibitors. They were considered 
at moderate UGI risk if only one of the latter risk 
factors was present. In the absence of any of these 
risk factors patients were considered to have a low 
UGI risk. Finally, we identifi ed each patient ’ s most 
recent available laboratory measurement of glomeru-
lar fi ltration rate (GFR) prior to the index date. If 
this GFR was    30 mL/min, patients were consid-
ered to have signifi cant renal insuffi ciency [26]. 
 The history of the diseases and conditions 
described above were assessed based on ICPC 
coding and free text search strings. In the case of 
diabetes and hyperlipidaemia, the use of respectively 
antidiabetic and lipid-modifying drugs, identifi ed 
based on ATC classifi cation code [27], was taken 
into account in addition to ICPC coding as proxy. If 
patients had a history of rheumatoid arthritis based 
on an ICPC code L88, this was defi ned as being 
severe if they also had a prescription in the year prior 
to the index date of specifi c antirheumatic agents, 
immunosuppressants, hydroxychloroquine, sulfasala-
zine, or cyclophosphamide. 
 NSAID prescription 
 For all included patients, the fi rst NSAID prescrip-
tion issued during the complaint episode was identi-
fi ed based on ATC classifi cation code [27]. Only 
NSAID prescriptions issued on the day of a consul-
tation for the MSK complaint were included. It 
has been suggested that the use of naproxen is less 
likely to increase cardiovascular risk than the use of 
other nsNSAIDs, and that the prescription of 
naproxen may be warranted in patients at a high CV 
risk [19,20,28]. In addition, there are indications 
that the risk of CV disease increases with NSAID use 
in a dose-dependent manner [29]. To examine 
whether GPs take these possibilities into account, a 
sensitivity analysis was conducted excluding naproxen 
and excluding all low-dosed nsNSAID and low-
dosed coxib prescriptions, which was defi ned as a 
prescribed daily dosage (PDD) smaller than half the 
defi ned daily dosage (DDD). 
 Statistics 
 Baseline characteristics of the moderate and high 
CV risk groups were compared with those of the 
low CV risk group using a chi-squared test for 
dichotomous variables and independent t-test for age 
as a continuous variable. Univariate analyses of 
potential predictors of NSAID prescription such as 
age, gender, CV risk, and UGI risk were conducted 
and unadjusted odds ratios (ORs) and their 95% 
confi dence intervals (CIs) were calculated by per-
forming logistic regression analyses. For the predic-
tor CV risk group, the same univariate logistic 
regression analyses were performed stratifi ed per 
UGI risk group. For this stratifi ed analysis, we also 
conducted multivariate analyses to present ORs 
adjusted for other predictors of nsNSAID and coxib 
prescription. Finally, the infl uence of CV risk on 
coxib and nsNSAID prescription was studied strati-
fi ed per time period, and ORs adjusted for the year 
of the MSK complaint episode within each time 
period were calculated, again using multivariate 
logistic regression analysis. All analyses were per-
formed using SPSS version 20 (SPSS, Chicago, IL). 
 Study approval 
 The study was approved by the Board of Directors 
of the IPCI database. 
 Results 
 Study cohort 
 Between 2000 and 2010, 804 261 adult patients 
aged over 18 years contributed data to the IPCI 
database. These patients were comparable to the 
general population of the Netherlands with regard 
to age and gender (mean age 40 years, 52% female 
versus 41 years, 51% female in the Dutch general 
population) [30]. Of these, 474 201 patients (59%) 
presented with a new MSK complaint and were 
included in the cohort. Baseline characteristics of 
all included patients are described in Table I. 
This table also shows the baseline characteristics 
per CV risk group. When comparing patients 
with a moderate or high CV risk with those with a 
low CV risk, statistically signifi cant differences 
were found for almost all characteristics with the 
exception of two symptomatic diagnoses of the 
MSK system. 
 Predictors of nsNSAID and coxib prescription 
 In total, 115 713 (24.7%) of all MSK complaint 
episodes were treated with an nsNSAID and 6456 
(1.4%) were treated with a coxib (Table II). The 
most frequently prescribed nsNSAIDs were 
diclofenac, naproxen, and ibuprofen (respectively 
58%, 13%, and 12% of all nsNSAIDs prescribed) 
and the most frequently prescribed coxibs were 
rofecoxib and etoricoxib (49% and 33% of all coxibs 
prescribed, results not shown in table). 
  Ischaemic cardiovascular risk and NSAID prescription  93
 Age, gender, and NSAID prescription in the six 
months prior to the index date were all predictive of 
nsNSAID and coxib prescription. The frequency of 
nsNSAID and coxib prescription also varied depend-
ing on the type of MSK complaint diagnosed. The 
prescription of coxibs was particularly high in patients 
suffering from arthritis. When corrected for age and 
gender, the odds of receiving a coxib were still ten-
fold in patients with arthritis when compared with 
those with complaints after trauma (adjusted OR 
9.8; 95% CI 8.4 – 11.5, not shown in table). The indi-
vidual CV risk factors were all associated with a 
higher chance of coxib prescription and a lower 
chance of nsNSAID prescription. Similarly, patients 
in the moderate and high CV risk group were sig-
nifi cantly more likely to receive a coxib than patients 
in the low CV risk group. The pattern for prescrip-
tion of nsNSAIDs was less clear, as they were pre-
scribed somewhat more frequently to patients with a 
moderate CV risk when compared with those with a 
low CV risk, but less frequently to those with a high 
CV risk than those with a low CV risk. UGI risk was 
also a strong predictor of coxib prescription, whereas 
a high UGI risk was associated with a lower chance 
of nsNSAID prescription. Patients with renal insuf-
fi ciency were less likely to be prescribed an nsNSAID 
and more likely to be prescribed a coxib than patients 
without renal insuffi ciency. 
 Table I. Baseline characteristics in the study population. 
Per CV risk group
Total
 (n    474 201)
 n (%)
Low CV risk
 (n    365 534)
 n (%)
Moderate CV risk
 (n    67 184)
 n (%)
High CV risk
 (n    41 483)
 n (%)
Age (mean   SD) 46.6    17.4 42.2    15.5 58.9    14.7 65.3    14.5
Age category:
18 – 35 years
 36 – 50 years
 51 – 65 years
   65 years
144 797 (30.5)
 147 497 (31.1)
 108 132 (22.8)
 73 775 (15.6)
138 809 (38.0)
 127 403 (34.9)
 69 526 (19.0)
 29 796 (8.2)
4 532 (6.7)
 14 773 (22.0)
 25 735 (38.3)
 22 144 (33.0)
1 456 (3.5)
 5 321 (12.8)
 12 871 (31.0)
 21 835 (52.6)
Female 256 015 (54.0) 196 550 (53.8) 38 906 (57.9) 20 559 (49.6)
NSAID prescription in six months prior to diagnosis 37 637 (7.9) 26 472 (7.2) 6 831 (10.2) 4 334 (10.4)
MSK complaint episode:
Symptomatic diagnosis
Back/neck
 Upper extremity
 Lower extremity
 Generalized/other
108 213 (22.8)
 82 026 (17.3)
 66 107 (13.9)
 59 986 (12.6)
86 957 (24.1)
 63 366 (17.3)
 49 802 (13.6)
 46 572 (12.7)
12 641 (18.8)
 11 810 (17.6) NS1 
 10 003 (14.9)
 8 035 (12.0)
7 615 (18.4)
 6 850 (16.5)
 6 302 (15.2)
 5 379 (13.0) NS2 
Arthritis 21 529 (4.5) 11 548 (3.2) 5 739 (8.5) 4 242 (10.2)
Infl ammatory arthritis
 Osteoarthritis
 Gout
4 676 (1.0)
 11 211 (2.4)
 5 642 (1.2)
2 874 (0.8)
 5 944 (1.6)
 2 730 (0.7)
1 045 (1.6)
 3 056 (4.5)
 1 638 (2.4)
757 (1.8)
 2 211 (5.3)
 1 274 (3.1)
Radiculopathy
 Trauma
 Other
25 409 (5.4)
 55 211 (11.6)
 55 720 (11.8)
19 180 (5.2)
 45 586 (12.5)
 41 523 (11.4)
3 822 (5.7)
 6 064 (9.0)
 9 070 (13.5)
2 407 (5.8)
 3 561 (8.6)
 5 127 (12.4)
Individual CV risk factors: 3 
Diabetes
 Hypertension
 Hyperlipidaemia
 MI/AP
 Stroke/TIA
 PAD
28 597 (6.0)
 63 841 (13.5)
 30 600 (6.5)
 27 118 (5.7)
 14 118 (3.0)
 5 715 (1.2)
 – 
 – 
 – 
 – 
 – 
 – 
20 847 (31.0)
 46 077 (68.6)
 18 129 (27.0)
 – 
 – 
 – 
7 750 (18.7)
 17 764 (42.8)
 12 471 (30.1)
 27 118 (65.4)
 14 118 (34.0)
 5 715 (13.8)
UGI risk group:
Low UGI risk
 Moderate UGI risk
 High UGI risk
335 556 (70.8)
 63 843 (13.5)
 74 802 (15.8)
305 168 (83.5)
 34 692 (9.5)
 25 674 (7.0)
22 003 (32.8)
 21 058 (31.3)
 24 123 (35.9)
8 385 (20.2)
 8 093 (19.5)
 25 005 (60.3)
Renal insuffi ciency 285 (0.1) 27 (0.01) 118 (0.2) 140 (0.3)
 Notes: CV: cardiovascular; NSAID: non-steroidal anti-infl ammatory drug; NS: non-signifi cant; MSK: musculoskeletal; MI: myocardial 
infarction; AP: angina pectoris; TIA:transient ischaemic attack; PAD: peripheral arterial disease; UGI: upper gastrointestinal. Comparisons 
were made for the moderate versus the low CV risk group and for the high versus the low CV risk group. All comparisons between 
moderate or high CV risk patients and low CV risk patients were statistically signifi cant (p - value    0.05), unless otherwise stated with the 
letters  ‘ NS ’ : non-signifi cant.  1 Comparison with low CV risk patients not statistically signifi cant, p - value 0.13.  2 Comparison with low CV 
risk patients not statistically signifi cant, p - value 0.19.  3 Risk factors used to defi ne low, moderate, and high CV risk groups. 
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 Infl uence of UGI risk 
 Table III shows the odds of coxib and nsNSAID 
prescription versus no NSAID prescription in 
patients with a high or moderate CV risk versus 
patients with a low CV risk, stratifi ed per UGI risk 
group. Within each UGI risk group, differences in 
prescription of nsNSAIDs and coxibs were found 
when comparing patients with a high or moderate 
CV risk with patients with a low CV risk. Notably 
for coxib prescription the direction of this difference 
varied depending on the UGI risk group. When 
adjusted for age, gender, previous NSAID prescrip-
tion, the type of MSK complaint diagnosed, and the 
presence of renal insuffi ciency, these differences 
diminished in magnitude but the same pattern still 
remained. 
 Prescription of nsNSAIDs and coxibs over time 
 Figure 1 shows the prescription of nsNSAIDs and 
coxibs over time. The prescription of coxibs initially 
increased over time in both high and low CV risk 
 Table II. Predictors of prescription of nsNSAIDs and coxibs. 
No NSAID 
prescribed
 (n    352 032)
 n (% 1 )
nsNSAID 
prescribed
 (n    115 713)
 n (% 1 )
Coxib
 prescribed
 (n    6 456)
 n (% 1 )
OR (95% CI)
 nsNSAID vs.
 no NSAID
 coxib vs.
 no NSAID
Age category:
18 – 35 years
 36 – 50 years
 51 – 65 years
   65 years
114 077 (78.8)
 105 154 (71.3)
 76 359 (70.6)
 56 442 (76.5)
29 948 (20.7)
 40 815 (27.7)
 29 688 (27.5)
 15 262 (20.7)
772 (0.5)
 1 528 (1.0)
 2 085 (1.9)
 2 071 (2.8)
1 (ref.)
 1.5 (1.5 – 1.5)
 1.5 (1.5 – 1.5)
 1.0 (1.0 – 1.1)
1 (ref.)
 2.2 (2.0 – 2.3)
 4.0 (3.7 – 4.4)
 5.4 (5.0 – 5.9)
Gender:
Male
 Female
159 766 (73.2)
 192 266 (75.1)
55 909 (25.6)
 59 804 (23.4)
2 511 (1.2)
 3 945 (1.5)
1 (ref.)
 0.9 (0.9 – 0.9)
1 (ref.)
 1.3 (1.2 – 1.4)
NSAID prescription in six months prior 24 860 (66.1) 11 688 (31.1) 1 089 (2.9) 1.5 (1.4 – 1.5) 2.7 (2.5 – 2.9)
MSK complaint:
Trauma
 Symptomatic diagnosis
49 345 (89.4) 5 605 (10.2) 261 (0.5) 1 (ref.) 1 (ref.)
Back/neck
 Upper extremity
 Lower extremity
 Generalized/other
70 464 (65.1)
 56 150 (68.5)
 54 211 (82.0)
 46 926 (78.2)
36 477 (33.7)
 24 558 (29.9)
 11 109 (16.8)
 12 308 (20.5)
1 272 (1.2)
 1 318 (1.6)
 787 (1.2)
 752 (1.3)
4.6 (4.4 – 4.7)
 3.9 (3.7 – 4.0)
 1.8 (1.7 – 1.9)
 2.3 (2.2 – 2.4)
3.4 (3.0 – 3.9)
 4.4 (3.9 – 5.1)
 2.8 (2.4 – 3.2)
 3.0 (2.6 – 3.5)
Arthritis 13 943 (64.8) 6 545 (30.4) 1 041 (4.8) 4.1 (4.0 – 4.3) 14.1 (12.3 – 16.2)
Infl ammatory arthritis
Osteoarthritis
Gout
3 027 (64.7)
 8 239 (73.5)
 2 677 (47.4)
1 386 (29.6)
 2 349 (21.0)
 2 810 (49.8)
263 (5.6)
 623 (5.6)
 155 (2.7)
4.0 (3.8 – 4.3)
 2.5 (2.4 – 2.6)
 9.2 (8.7 – 9.8)
16.4 (13.8 – 19.6)
 14.3 (12.3 – 16.6)
 10.9 (8.9 – 13.4)
Radiculopathy
 Other
16 699 (65.7)
 44 294 (79.5)
8 269 (32.5)
 10 842 (19.5)
441 (1.7)
 584 (1.0)
4.4 (4.2 – 4.5)
 2.2 (2.1 – 2.2)
5.0 (4.3 – 5.8)
 2.5 (2.2 – 2.9)
Individual CV risk factors:
No CV risk factors
 Diabetes
 Hypertension
 Hyperlipidaemia
 MI/AP
 Stroke/TIA
 PAD
270 758 (74.1)
 21 113 (73.8)
 48 168 (75.6)
 23 118 (75.5)
 21 113 (77.9)
 11 209 (79.4)
 4 484 (78.5)
90 615 (24.8)
 6 864 (24.0)
 14 261 (22.4)
 6 853 (22.4)
 5 356 (19.8)
 2 626 (18.6)
 1 117 (19.5)
4 161 (1.1)
 620 (2.2)
 1 312 (2.0)
 629 (2.1)
 649 (2.4)
 283 (2.0)
 114 (2.0)
1 (ref.)
 1.0 (1.0 – 1.0)
 0.9 (0.9 – 0.9)
 0.9 (0.9 – 0.9)
 0.8 (0.7 – 0.8)
 0.7 (0.7 – 0.7)
 0.7 (0.7 – 0.8)
1 (ref.)
 1.9 (1.8 – 2.1)
 1.8 (1.7 – 1.9)
 1.8 (1.6 – 1.9)
 2.0 (1.8 – 2.2)
 1.6 (1.5 – 1.9)
 1.7 (1.4 – 2.0)
CV risk group:
Low CV risk
 Moderate CV risk
 High CV risk
270 758 (74.1)
 48 970 (72.9)
 32 304 (77.9)
90 615 (24.8)
 16 852 (25.1)
 8 246 (19.9)
4 161 (1.1)
 1 362 (2.0)
 933 (2.2)
1 (ref.)
 1.0 (1.0 – 1.1)
 0.8 (0.7 – 0.8)
1 (ref.)
 1.8 (1.7 – 1.9)
 1.9 (1.8 – 2.0)
UGI risk group:
Low UGI risk
 Moderate UGI risk
 High UGI risk
248 705 (74.1)
 45 724 (71.6)
 57 603 (77.0)
83 753 (25.0)
 16 792 (26.3)
 15 168 (20.3)
3 098 (0.9)
 1 327 (2.1)
 2 031 (2.7)
1 (ref.)
 1.1 (1.1 – 1.1)
 0.8 (0.8 – 0.8)
1 (ref.)
 2.3 (2.2 – 2.5)
 2.8 (2.7 – 3.0)
Renal insuffi ciency:
No renal insuffi ciency
Renal insuffi ciency
351 801 (74.2)
231 (81.1)
115 666 (24.4)
47 (16.5)
6 449 (1.4)
7 (2.5)
1 (ref.)
0.6 (0.5 – 0.8)
1 (ref.)
1.7 (0.8 – 3.5)
 Notes: nsNSAID: non-selective non-steroidal anti-infl ammatory drug; NSAID: non-steroidal anti-infl ammatory drug; MSK: 
musculoskeletal; CV: cardiovascular; MI: myocardial infarction; AP: angina pectoris; TIA: transient ischaemic attack; PAD: peripheral 
arterial disease; UGI: upper gastrointestinal.  1 Row percentage. 
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patients, until 2004, after which a sharp decrease is 
observed. During the peak year of 2004, the odds of 
prescription of coxibs in high CV risk patients was 
around three times higher than in 2000 and in 2005 
(OR 2.9, 95% CI 2.2 – 3.7 and OR 3.4, 95% CI 2.5 –
 4.6 for 2004 versus respectively 2000 and 2005, not 
shown in fi gure). 
 The odds of coxib prescription were signifi cantly 
higher in patients at high CV risk than in patients at 
low CV risk (Table IV), not only between 2000 and 
2004 but also between 2005 and 2010. The odds of 
nsNSAID prescription remained signifi cantly lower 
in patients at high CV risk than in patients at low CV 
risk in both time periods. In a sensitivity analysis in 
which prescriptions of naproxen and prescriptions 
with a PDD smaller than half the DDD were 
excluded, the odds of prescription of an nsNSAID 
or coxib versus no NSAID, in patients with a high 
CV risk versus patients with a low CV risk, were 
almost the same as that of all nsNSAIDs or coxibs 
versus no NSAIDs in both time periods (OR 0.8, 
95% CI 0.8 – 0.8 and OR 0.7, 95% CI 0.7 – 0.8, for 
 Table III. Prescription of coxibs and nsNSAIDs versus no NSAID in moderate and high CV risk patients versus low CV 
risk patients per UGI risk group. 
OR (95% CI) Adj. OR (95% CI) 2 
UGI risk 
group
CV risk 
group
Number 
of 
patients
No NSAID
 n (% 1 )
nsNSAID
 n (% 1 )
Coxib
 n (% 1 )
nsNSAID
 vs. no 
NSAID
coxib
 vs. no 
NSAID
nsNSAID
 vs. no 
NSAID
coxib
 vs. no 
NSAID
Low Low 305 168 226 617 (74.3) 75 915 (24.9) 2 636 (0.9) 1 (ref.) 1 (ref.) 1 (ref.) 1 (ref.)
Moderate 22 003 15 842 (72.0) 5 836 (26.5) 325 (1.5) 1.1 (1.1 – 1.1) 1.7 (1.5 – 1.9) 0.9 (0.9 – 0.9) 1.1 (1.0 – 1.2)
High 8 385 6 246 (74.5) 2 002 (23.9) 137 (1.6) 1.0 (0.9 – 1.0) 1.9 (1.6 – 2.3) 0.8 (0.8 – 0.8) 1.3 (1.1 – 1.5)
Moderate Low 34 692 24 776 (71.4) 9 164 (26.4) 752 (2.2) 1 (ref.) 1 (ref.) 1 (ref.) 1 (ref.)
Moderate 21 058 14 945 (71.0) 5 708 (27.1) 405 (1.9) 1.0 (1.0 – 1.1) 0.9 (0.8 – 1.0) 1.0 (1.0 – 1.1) 0.9 (0.8 – 1.2)
High 8 093 6 003 (74.2) 1 920 (23.7) 170 (2.1) 0.9 (0.8 – 0.9) 1.0 (0.8 – 1.1) 0.8 (0.8 – 0.9) 1.0 (0.8 – 1.2)
High Low 25 674 19 365 (75.4) 5 536 (21.6) 773 (3.0) 1 (ref.) 1 (ref.) 1 (ref.) 1 (ref.)
Moderate 24 123 18 183 (75.4) 5 308 (22.0) 632 (2.6) 1.0 (1.0 – 1.1) 0.9 (0.8 – 1.0) 1.0 (1.0 – 1.1) 0.9 (0.8 – 1.0)
High 25 005 20 055 (80.2) 4 324 (17.3) 626 (2.5) 0.8 (0.7 – 0.8) 0.8 (0.7 – 0.9) 0.8 (0.7 – 0.8) 0.8 (0.7 – 0.9)
 Notes: nsNSAID: non-selective non-steroidal anti-infl ammatory drug; NSAID: non-steroidal anti-infl ammatory drug; CV: cardiovascular; 
UGI: upper gastrointestinal.  1 Row percentage.  2 Adjusted for age, gender, prescription of NSAIDs in six months prior, type of MSK com-
plaint, and presence of renal insuffi ciency. 
 Figure 1. Percentage of patients with a high CV risk and with a low CV risk prescribed an nsNSAID or a coxib per year. 
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nsNSAID versus no NSAID in 2000 – 2004 and 
2005 – 2010 respectively; OR 2.0, 95% CI 1.8 – 2.2 
and OR 1.9, 95% 1.7 – 2.2 for coxib versus no NSAID 
in 2000 – 2004 and 2005 – 2010 respectively, not 
shown in table). 
 Discussion 
 Statement of principal fi ndings 
 In this study, we examined the prescription of 
NSAIDs in the treatment of MSK complaints by 
GPs over the course of the last decade, in which 
evidence emerged regarding the CV risks of these 
drugs. We found that one-quarter of all patients pre-
senting with a MSK complaint were treated with an 
NSAID. Prescription varied widely depending on the 
type of MSK complaint diagnosed. Coxibs gained in 
popularity during the fi rst fi ve years of marketing in 
the Netherlands, with prescription among high CV 
risk patients in 2004 almost three times higher than 
in 2000. After rofecoxib was removed from the mar-
ket, a decrease in coxib prescription was observed. 
The decrease in coxib prescription observed after 
2004 occurred not only in patients with a high CV 
risk, but equally in patients with a low CV risk, even 
after their use was contraindicated in these patients 
by the European Medicines Agency in 2005 [14]. 
Conversely, nsNSAIDS were prescribed less fre-
quently in patients with a high CV risk than in 
patients with a low CV risk throughout the study 
period. These observed differences in prescription 
between CV risk groups can be partly explained by 
the overlap between CV risk and UGI risk. When 
stratifi ed for UGI risk, the odds of both nsNSAID 
and coxib prescription decreased with increasing 
CV risk in patients at moderate or high UGI risk. 
Interestingly, however, for coxibs the opposite pat-
tern was observed for patients with a low UGI risk. 
When corrected for other predictors, within the low 
UGI group coxibs were still prescribed more fre-
quently in those with a high CV risk than in those 
with a low CV risk, suggesting that other factors play 
a role in GPs ’ decision to prescribe these drugs. 
 Strengths and weaknesses of the study 
 The strength of this study is that it was conducted 
in a database containing a large number of patients 
refl ecting the Dutch general population. Nonethe-
less, some limitations should be considered when 
reviewing the results. First, only patients presenting 
with an ICPC-coded MSK complaint were included 
in the cohort. As some GPs may apply the ICPC 
coding more diligently than others, this may have led 
to an underestimation or overestimation of NSAID 
treatment, if the prescribing behaviour of GPs is in 
any way related to their tendency to apply the ICPC 
coding. Second, we did not have any information on 
over-the-counter (OTC) use of analgesics. Although 
coxibs are not available without prescription in the 
Netherlands, nsNSAIDs are freely available. While 
this is important, our objective in this study was to 
determine the association between the cardiovascular 
risk profi le of a patient and NSAID prescription by 
the GP. 
 Strengths and weaknesses in relation to other studies 
 Various studies examining changes in NSAID pre-
scription in primary care over the past decade have 
been published [31 – 34]. However, few large-scale 
studies have focused specifi cally on the infl uence of 
CV risk on the prescription of NSAIDs by GPs, 
which was the aim of the present study. One prior 
study did investigate this in the primary care popula-
tion as we did, but it only reported on the years 2000 
to 2004, before evidence emerged of the CV risk of 
NSAIDs [35]. Other studies which have reported on 
CV risk and the use of NSAIDs both before and after 
 Table IV. Prescription of coxibs and nsNSAIDs versus no NSAID in moderate and high CV risk patients versus low CV 
risk patients per time period. 
Adj. OR (95% CI) 2 
Time period
CV risk 
group
Number 
of patients
No NSAID
 n (% 1 )
nsNSAID
 n (% 1 )
Coxib
 n (% 1 )
nsNSAID
 vs. no NSAID
coxib
 vs. no NSAID
2000 – 2004 Low 181 443 127 912 (70.5) 50 670 (27.9) 2 861 (1.6) 1 (ref.) 1 (ref.)
Moderate 27 421 18 939 (69.1) 7 703 (28.1) 779 (2.8) 1.0 (1.0 – 1.1) 1.9 (1.7 – 2.1)
High 18 574 13 619 (73.3) 4 349 (23.4) 606 (3.3) 0.8 (0.8 – 0.8) 2.0 (1.8 – 2.2)
2005 – 2010 Low 184 091 142 846 (77.6) 39 945 (21.7) 1 300 (0.7) 1 (ref.) 1 (ref.)
Moderate 39 763 30 031 (75.5) 9 149 (23.0) 583 (1.5) 1.1 (1.1 – 1.1) 2.3 (1.9 – 2.4)
High 22 909 18 685 (81.6) 3 897 (17.0) 327 (1.4) 0.8 (0.7 – 0.8) 1.9 (1.7 – 2.2)
 Notes: CV: cardiovascular; NSAID: non-steroidal anti-infl ammatory drug; nsNSAID: non-selective non-steroidal anti-infl ammatory 
 drug.  1 Row percentage.  2 Adjusted for year of MSK complaint episode within the time period. 
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rofecoxib withdrawal in 2004 [36,37] were not pop-
ulation-based. In addition, in these studies the CV 
risk profi le of the patients was determined based on 
surrogate pharmacy markers. The strength of our pop-
ulation-based study lies in the fact that we were able 
to identify all relevant risk factors by conducting free 
text searches, assessing ICPC-codes and prescriptions 
of medication, using GP medical records which form 
a complete record of each patient ’ s medical data. 
 Meaning of the study 
 Although international guidelines have provided rec-
ommendations on NSAID prescription in patients with 
CV risk factors [19,20], as of yet no national Dutch 
guideline has been published specifi cally on this topic. 
The most recent Dutch guideline specifi cally on NSAID 
prescription was published in 2003 [25], at which point 
in time little was known about the CV risks associated 
with NSAID use. Over time, prescription of NSAIDs 
has decreased in all risk groups, which might relate to 
awareness of GPs regarding risks associated with 
NSAIDs. Nonetheless, overall one in fi ve patients with 
a high CV risk presenting with a new MSK complaint 
received an NSAID. It appears that GPs do not fully 
consider the CV risks associated with NSAID use when 
prescribing NSAIDs in these patients, indicating that 
there is still room for improvement. 
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